Introduction
Cancer patients and in particular bone marrow transplantation (BMT) recipients are at risk for the development of prolonged T cell deficiency associated with cytotoxic therapies or immunosuppressive treatments. These patient populations would greatly benefit from protocols boosting antigen-specific T cell immunity 1 . The organ of T cell development, the thymus, is therefore an obvious target organ for immunotherapeutic
strategies, yet thymus-based approaches have traditionally been underutilized in clinical protocols to improve immunity. A main reason for this lack of thymus-centered trials has to do with the fact that thymic cell populations are highly sensitive and prone to injury. In addition, bone marrow (BM)-derived circulating thymus-seeding T cell progenitors are of critical importance for proper thymic function, and the lack thereof, such as during periods of lymphopenia, compromises thymopoiesis 2 . As such, overcoming reduced thymic function, be it due to medical conditions or treatments, stress, or age-related thymic involution 3, 4 , is always challenging, and clinical protocols designed to boost endogenous thymic function by administration of thymopoietic growth factors 5 have only been mildly successful to date. Protocols for adoptive transfer of naïve or antigen-specific T cells have been developed in an attempt to boost T cell immunity, but persistence of transferred T cells can be an issue 1 , and availability of suitable donor cells can be a major limiting factor. Therefore there is clearly a need for alternate clinically feasible strategies to improve thymopoiesis and T cell immunity. Our study demonstrates that image-guided injection of the thymus with cells or drugs presents promising opportunities for clinical immunotherapy.
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From Cs source. BMT recipients were transplanted with intravenously injected bone marrow cells (5 -10 × 10 6 ) that were removed aseptically from femurs and tibias followed by T cell depletion with anti-Thy-1.2 and low-TOX-M rabbit complement (Cedarlane Laboratories, Burlington, NC, USA).
Thymic irradiation (3,300 cGy) was performed with a X-RAD 320 orthovoltage energy X-ray unit (Precision X-Ray, North Branford, CT, USA). Animals were shielded with a lead shield allowing radiation exposure of the thymic area only.
In GVT experiments, animals received 50,000 B16 F10 melanoma cells (H-2 For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From caliper, and mice were sacrificed when the diameter exceeded 1 cm, tumors became ulcerated, or mice showed discomfort.
Ultrasound-guided intrathymic injections. Mice were anesthetized using continuous administration of 1-4% isoflurane anesthesia via a nose cone and precision calibrated vaporizer. After induction of anesthesia, mice were positioned supine on a heated 37°C animal platform of the Vevo Imaging Station (Visualsonics, Toronto, Ontario Canada).
Mice were secured to the stage by applying transparent medical adhesive tape (Covidien, Mansfield, MA, USA) to their hind and fore limbs. The previously epilated skin of the upper thorax was sterilely prepared using Chloraprep One-Step (CareFusion, Leawood, KS, USA), a chlorhexidine gluconate wash. Ultrasound imaging was performed with the Vevo2100 (Visualsonics) using a MS-550S 40 mHz linear transducer using an imaging depth of 6-7 mm. After the probe was sheathed with a sterile latex cover (Sheathing Technologies, Morgan Hill, CA, USA), sterile Aquasonic 100 gel (Parker Laboratories, Fairfield, NJ, USA) was then applied to the transducer to produce several millimeters of stand-off during imaging. While sterilely gloved, the radiologist moved the needle of a 30-gauge insulin syringe (BD, Franklin Lakes, NJ, USA) containing 10 μ l of injectate in the stand-off gel under the transducer until it was adequately visualized at the skin surface, and then it was inserted into the thymus gland via a percutaneous trajectory away from blood vessels. Once the needle tip was within the thymus, syringe contents were injected during sonographic visualization. 
In vivo bioluminescence imaging. Intravital monitoring of intrathymically injected LSK cells was performed by in vivo bioluminescence imaging (BLI). Mice received D-

Results
Intrathymic injection of multipotent stem cells produces functional donor T cells
In targeting the need for additional clinically feasible strategies improving thymopoiesis and T cell immunity we developed a minimally invasive interventional radiology method for aseptic intrathymic injection (ITI) based on ultrasound-guided freehand injection (supplemental Figure 1) Figure 2) . We therefore used cell doses of at least 2,000 LSK cells (ranging from 3,000 to 10,000 cells per injection) for all subsequent experiments. In order to establish a clinically applicable cell therapy strategy, we decided to first focus on ITI 1 0 of syngeneic HSPCs (equivalent to autologous CD34 + human HSPCs). To facilitate engraftment, recipients were exposed to sublethal irradiation (usually in the form of total body irradiation (TBI)). We found that when intrathymically injected two to three hours after sublethal TBI, syngeneic HSPCs had excellent thymus-repopulating capacity (Figures 1A-C) and resulted in robust peripheral T cell reconstitution ( Figure 1D ).
Overall thymic cellularity was not increased compared with irradiated controls (data not shown). More than 90% progeny of intrathymically injected HSPCs differentiated into T cells ( Figure 1E ) that were characterized by a normal CD4 to CD8 ratio ( Figure 1E ), predominance of naive and central memory phenotypes (Figure 2A ), appropriate cytokine production in response to non-specific stimulation with a strong mitogen ( Figure 2B ), and a diverse T cell receptor repertoire ( Figure 2C ). Of note, thymic conditioning with focal thymic irradiation was as effective as sublethal TBI, whereas injection of syngeneic
HSPCs into the thymus of non-conditioned mice resulted in only minimal donor T cell reconstitution, indicating that even in the absence of rejection the number of available precursor cell niches is still a limiting factor ( Figure 2D ).
Intrathymic injection of HSPCs generates long-lasting donor T cells after bone marrow transplantation
We next evaluated the fate of intrathymically injected HSPCs in the setting of bone marrow transplantation. Syngeneic or allogeneic recipients were exposed to lethal TBI, followed by intravenous administration of T cell-depleted BM as well as ITI of HSPCs that were congenic with the BM donor. Consistent with previous studies, we found
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org are not known to exist in the thymus under physiological conditions. We were also able to detect intrathymic myeloid cells ( Figure 4D ) and dendritic cells (data not shown)
derived from intrathymically injected HSPCs, indicating that despite the highly specialized thymic microenvironment it is possible for injected multipotent HSPCs to give rise to low frequencies of non-T lineage cells 14 . These cells, even though representing only a very small proportion of thymocytes, may play an important role especially in the allogeneic setting by contributing to thymic negative selection resulting in donor tolerance.
Intrathymic injection of drugs can improve thymopoiesis of aged mice
One potential limitation of any immunotherapeutic strategy based on intrathymic injection is the difficult visualization of the thymus with increasing age of the recipient.
Involution of the human thymus involves replacement of thymic epithelial cells by adipocytes 15 , therefore differentiating between bioactive thymic tissue and adipose tissue may be challenging in aged recipients. Nevertheless, it can often still be accomplished by an experienced radiologist 16 . In aging mice, the thymus significantly decreases in size but fatty infiltration does not occur. We found that ultrasound imaging allows for accurate assessment of the thymic anatomy in aged mice, and we were able to perform ultrasoundguided free-hand ITIs in up to two-year old mice. We established rejuvenated thymopoiesis of sublethally irradiated aged mice by ITI of syngeneic young HSPCs ( Figure 5A ), although overall thymic cellularity was not increased compared with irradiated controls. This was similar to our observation in young mice (data not shown).
We also found a higher proportion of non-T lineage progeny of intrathymically injected populations, and did not differentially affect splenic T cell subsets (data not shown).
Next, we repeated the same experiment in aged mice ( Figure 5E ). While the benefit of pre-irradiation IL-7 was not as clear as in young mice, high-dose IL-7 again did not
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From appear to have any negative effect on thymopoiesis. Overall, the most efficacious IL-7 dose for radioprotection of the thymus was therefore 500 ng. Based on our findings in aged as well as in irradiated recipients we decided to test if combination treatment with KGF and IL-7 had synergistic effects on thymic recovery of aged recipients from radiation-induced injury. Aged mice were conditioned with a single ITI of KGF to increase thymic cellularity. Four weeks later, this was followed by a single injection of IL-7 to confer radioprotection, and all animals were exposed to sublethal TBI 24 hours later. We found that in contrast to our observations in young mice, only the combination of KGF and IL-7 (but not IL-7 alone) resulted in increased thymocyte numbers (mainly due to the effect on CD4 and CD8 DP thymocytes) ( Figure 5F and data not shown), as well as increased thymic epithelial cell numbers (supplemental Figure 6A) four weeks after irradiation. Notably, KGF alone was sufficient to enhance the generation of mature T cells ( Figure 5G and supplemental Figure 6B ) four weeks after irradiation. Our data suggest that innovative uses of IL-7 and KGF can contribute to further optimize the efficacy of thymus-based cell therapy.
Intrathymic injection HSPCs expressing a transgenic TCR facilitates generation of antigen-specific T cells
Based on our above-described findings we hypothesized that ITI of HSPCs can enable the establishment of long-lasting antigen-specific T cell immunity. We tested our theory in a mouse model of melanoma where B16 melanoma cells were administered by intradermal injection four weeks following syngeneic BMT. We first compared anti- Figure 6E ). Since Gp100 is a MHC class I restricted antigen, we did not observe any CD4 + tetramer + peripheral T cells.
T cells derived from Pmel-1 HSPCs (both following intravenous injection and ITI)
predominantly displayed a naive and central memory phenotype ( Figure 6F ). This data set, even though not representing a therapeutic tumor model, underscores the potential of our approach for tumor immunosurveillance and targeted immunotherapy.
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Discussion
The goal of this study was to explore innovative strategies to improve the quantity (T cell numbers), and more importantly the quality (desired antigen specificity) of thymic output in clinically relevant models of thymic insufficiency. Intrathymic injection allows the manipulation of thymic function; we therefore attempted to develop an improved method for intrathymic injection that could facilitate the implementation of novel immunotherapeutic approaches. We were able to accomplish this goal by establishing a method for image-guided free-hand intrathymic injection, a technique that is minimally invasive and timesaving, thus facilitating large-scale experiments. Moreover, this method is clinically applicable.
Previous preclinical cell therapy studies using ITI were performed in recipients with genetic T cell deficiencies, requiring no thymic conditioning when administering syngeneic BM cells 12 , and chemotherapy when administering allogeneic BM cells 11 . We were able to demonstrate that an immunocompetent recipient can easily be conditioned for ITI by using sublethal TBI or even less toxic thymic irradiation. Moreover, instead of using lineage-marker negative BM, we established purified LSK cells, the equivalent of human CD34+ HSPCs, as the cell source for this immunotherapy. It is important to note that the cell doses used in this study are likely to be clinically feasible. In most experiments we injected only a small fraction of the total number of LSK cells that can routinely be isolated from a single donor. Intrathymic injection of syngeneic HSPCs was associated with virtually life-long intrathymic persistence (15 months follow-up, equivalent to 50 human years) and continuous T cell generation. Importantly, we were able to identify progeny of intrathymically injected HSPCs resembling long-term HSCs.
For personal use only. on June 7, 2017 . by guest www.bloodjournal.org From Our phenotypic findings combined with the observed long-term intrathymic persistence are suggestive of self-renewal 24, 25 . Being able to exploit this phenomenon for life-long immunosurveillance of cancer or life-threatening viral infections, or to promote elimination of minimal residual disease, would be especially beneficial for cancer patients who are at high risk for malignant relapse or recurrence of a latent infection.
With this in mind we were indeed able to demonstrate feasibility and efficacy of antigenspecific T cell immunity established by ITI of multipotent HSPCs expressing a transgenic TCR. Finally, we were able to develop strategies to overcome critical challenges and limitations of thymus-based approaches, such as thymic damage due to radiation-induced injury or age-related thymic involution. We demonstrate that KGF or IL-7, when administered intrathymically, can be effective with a very low single dose, in contrast to the multidose systemic injection approach traditionally used for these agents. Our study is the first to report radioprotective properties of pre-irradiation IL-7 administration, a cytokine that is usually not started until several weeks after transplant when used in the BMT setting. Moreover, a single ITI of KGF at a dose that is 150-times lower than the standard cumulative dose used for systemic administration has a sustained positive effect on thymopoiesis of aged mice even in the setting of radiation-induced injury. Taken together, our findings indicate that even an aged thymus can be targeted and may be responsive to interventions designed to optimize the generation of naïve T cells.
In conclusion, our studies introduce a novel method for the establishment of longlasting T cell immunity to specific antigens, enabled by a single ITI of TCR transgenic multipotent HSPCs. Importantly, an aged recipient, whose thymus has degenerated over time, can also be successfully treated. To ensure success, pre-treatment with a thymic Representative histograms/plots of one of four samples are presented.
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